Luis A. Diaz

Luis A. Diaz, Jr., M.D., has been the head of the division of solid tumor oncology at the Memorial Sloan Kettering Cancer Center since December 2016. From 2004 to December 2016, he was a faculty member and physician at the Johns Hopkins University School of Medicine. He has founded several biotechnology companies, including Epitope, Inostics, PapGene (Thrive) and Personal Genome Diagnostics, Inc. Dr. Diaz’s early work provided the first definitive evidence for using circulating tumor DNA as cancer biomarker for screening, monitoring, and detection of occult disease. He discovered the therapeutic link between immunotherapy and cancer genetics in patients with mismatch repair deficient tumors, which led to the first tumor agnostic FDA approval for tumors with this genetic lesion and the first cancer study, published in 2022, that resulted in a 100% complete remission rate. Dr. Diaz has served on the board of Jounce Therapeutics, Inc. since 2017. He is the recipient of numerous awards and honors and in 2021 was appointed by President Biden to the National Cancer Advisory Board of the National Institutes of Health. Dr. Diaz has been a director of Quest Diagnostics since May 2023. He has extensive experience in medicine, science and healthcare and strong management and strategic planning experience with enterprises engaged in medicine, science and healthcare.